Prix InnoCare Pharma Ltd (09969.HK)

InnoCare Pharma Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Beijing, Beijing and currently employs 1,146 full-time employees. The company went IPO on 2020-03-23. InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The firm focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The firm's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The firm is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The firm conducts its businesses in domestic and overseas markets.